RxDoctor Payments DataLook up a doctor →

Robert Ruben, MD

Gastroenterology · Somersworth, NHNPI 1457354565

Payments from drug & device makers

$35,522in general payments, 2019–2025

Across 371 payments — averaging $95.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$29K
  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$735
  • Takeda Pharmaceuticals U.S.A., Inc.$645
  • Johnson & Johnson$490
  • Boston Scientific$457
  • plus $3K from 29 others
$35,000in research payments, 2019–2025

Across 6 payments — averaging $5833.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$35K

What the payments were for

  • Speaking & faculty fees$25,12571%
  • Travel & lodging$2,8988%
  • Food & beverage$7,44321%
  • Education$560%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,522 in reported general payments places this provider in the 85th percentile of 91 gastroenterology providers in New Hampshire.

See all gastroenterology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$538,702
Medicare patients
1,070
Services billed
14,294

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GattexTeduglutide11$1,015,610
LinzessLinaclotide67$58,047
CreonLipase/Protease/Amylase11$39,949
Mesalamine44$20,532
Dexlansoprazole DrDexlansoprazole15$6,462
Pantoprazole Sodium368$6,350
Ursodiol16$3,847
Balsalazide Disodium13$3,504
Dicyclomine Hcl121$3,375
Omeprazole132$2,543
Colestipol Hcl15$2,134
Esomeprazole Magnesium37$1,754
Rabeprazole Sodium23$1,587
Mercaptopurine13$1,508
Famotidine83$1,416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gattex$645$1,015,61011 claims
AbbVieLinzess, Creon$1,785$97,99678 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 91 gastroenterology providers in New Hampshire.

Other gastroenterology in Somersworth

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →